Month: November 2014
The Active Pharmaceutical Ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
DelveInsight API Insights’ focus uncovers the commercial manufacturing status of 1600 Active Pharmaceutical ingredient molecules and above. The Report opens the opportunities for Generic Industries, Drug Companies as well as API Manufacturers to keep them updated on the API front all across the globe. The data in the report will provide you with the strategic move for long term successful business.
DelveInsight is serving thousands of Companies and associated people in decision making in this highly competitive world.
Get the best out of Pharm API. Pharm API guides you at every step of the API buisness leading to successful milestones.
Drug Reports starts from USD 500
Indication Reports starts from USD 1250
- Identification of API Manufacturers for US, Europe, India and China.
- Potential API identification to add into the Company’s product portfolio.
- Global Coverage of API Business Opportunities
- Forecasted drug global sales for 2014-2016
- Modulate production to reflect demand
- Understand current market and growth dynamics
- Estimate patent expiry dates for competitor drugs for your interested indication.
- Analyze the impact of patent expiry and identify drugs that are vulnerable to generic competition.
The reports give deep details on the API and API Manufacturers information across the globe with their patent expiration details and Drug global sales forecasting till 2016. We can also customize these reports on the basis of clients needs. The reports are available on some of the leading market resellers website such as Report Linker/Report Buyer Market Reports Japan, Market Publishers, MarketReserachReports, MarketResearch.com, JSB Market Research, Reportstack and Bharat Book Bureau.
Or you can directly contact us for the Reports by emailing us at firstname.lastname@example.org
Get Market Intelligence of Hemophilia Market with DelveInsight
The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor.
Currently about 20,000 people have hemophilia in the US; about 80% of them have hemophilia A, and 3,000 to 4,000 have hemophilia B. About 400 US babies with hemophilia are born each year. Von Willebrand disease is the most common bleeding disorder, affecting about 1% of the population.
In the Haemophilia world; diseases are cured by factors like Hemophilia A patients use factor VIII (FVIII), Hemophilia B patients use factor IX (FIX) and VWD patients use factor VIII with VWF (VWF/FVIII complex).
The Recombinant hemophilia market is set to take over the market place with the long acting treatments in the major markets; the US, France, Germany, Italy, Spain, UK and Japan by the beginning in the US in 2014 and the European countries (5EU) in 2015. The launch of Biogen Idec and Sobi’s long-acting therapies for hemophilia A and B will affect the position of Baxter, Bayer and Pfizer’s market- leading therapies. These long acting therapies will give a significant increase in sales to the hemophilia market.
Understand Haemophilia Market with our Reports. Get the deeper understanding of the long-acting recombinant factor VIII and factor IX therapies and its impact on the on current treatments for hemophilia A and B and VWD. Global sales forecasting of the Hemophilia Market till 2016 for the individual marketed products. Get access over pipeline drugs, the technology, stage of development, their targets, mechanism of action with our Pipeline reports.
Contact Us at email@example.com
Our reports can be customized to include any specific information that you might interested in. Send us an email with your requirements and our team will get back to you instantly.